National Lab Briefs

To say that Robert Hunter has made enemies in his first year as director of the Department of Energy’s Office of Energy Research is an understatement. In fact, the real question may be just how many friends he still has left. Earlier this month, Congress held a rare three-day hearing on the troubled magnetic fusion program largely to build a case against Hunter and his plans to deemphasize tokamak fusion in favor of more work on a laser-based method known as inertial confinement fusion. A

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

To say that Robert Hunter has made enemies in his first year as director of the Department of Energy’s Office of Energy Research is an understatement. In fact, the real question may be just how many friends he still has left. Earlier this month, Congress held a rare three-day hearing on the troubled magnetic fusion program largely to build a case against Hunter and his plans to deemphasize tokamak fusion in favor of more work on a laser-based method known as inertial confinement fusion. After two days of consensus building with a stream of scientists who support building the $700 million Compact Ignition Tokamak at the Princeton Plasma Physics Lab, the House Science, Space, and Technology investigations subcommittee spent its third day trying to learn from Hunter why he disagreed. “If we build a CIT that does not ignite, we can’t rely on it to lead us in our future ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies